Although not currently available to the general public, psilocybin has shown promise in treating a handful of mental health conditions when administered by medical professionals and used alongside talk therapy and/or integration therapy.
Treatment-resistant depression (TRD). COMPASS Pathways’ latest clinical trials focused on psilocybin dosage efficacy, alongside psychological support, against TRD. The study found that a single 25 milligram dose of psilocybin significantly reduced participants’ depression compared to 10 milligrams and 1 milligram doses. Depression and anxiety. Studies have shown that doses of 0.20 milligrams/kilograms to 0.40 milligrams/kilograms reduce the depression and anxiety felt by individuals living with cancer.
This is an important breakthrough for end-of-life care. A small study by Johns Hopkins’ Center for Psychedelic and Consciousness Research found that immediate psilocybin-assisted therapy (compared to delayed treatment) improved assessments of participants’ depression. Participants were not on antidepressant medications at the time of the trial. Anorexia nervosa.
A small 2022 exploratory study on individuals living with anorexia nervosa found that psilocybin therapy (with a 25-milligram dose) significantly reduced 40% of participants’ eating disorder psychopathology (dysfunction), including issues around body shape, and eating concerns. Researchers report 90% of participants found the experience “meaningful and therapeutic.”
Check our video out now on our Youtube channel to find out more about #Psilocybin.
Don’t forget to like, subscribe and hit the notification bell to be updated weekly with news concerning Medicine on Youtube @TheMedicalClinic.
For more info, contact us at our brand new NY Hell’s Kitchen clinic at +1 646 647 9163 (dial or text).
